Blood Res.  2020 Jul;55(S1):S27-S31. 10.5045/br.2020.S005.

Optimal therapy for adolescents and young adults with acute lymphoblastic leukemia-current perspectives

• Lee JW

• KMID: 2504739
• DOI: http://doi.org/10.5045/br.2020.S005

Abstract

Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) have worse prognosis than children. Differing biology of ALL may account for some of this disparity in outcome, with AYA patients having far lower incidence of good risk cytogenetic abnormalities, and higher proportion of patients with genetic lesions associated with inferior survival such as Ph-like ALL. Actual chemotherapy may also contribute to differences in outcome. Retrospective studies have shown that AYA patients treated on pediatric-based regimens had higher survival than those treated with adult regimens; the superiority of pediatric protocols has also been proven in several prospective comparative trials. Increase in rate of enrollment of AYA patients in clinical trials may further improve outcome. Cure based on chemotherapy may further limit the role of allogeneic hematopoietic cell transplantation (HCT) in AYA patients. The unique biology of AYA ALL may allow for novel methods of targeted therapy, while immunotherapy, the efficacy of which has been proven for both children and adults, may also play a major role in the treatment of relapsed/refractory ALL.

Keyword

Acute lymphoblastic leukemia; Adolescents; Young adults; Ph-like ALL

Reference

1. Boissel N, Auclerc MF, Lhéritier V, et al. 2003; Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 21:774–80. DOI: 10.1200/JCO.2003.02.053. PMID: 12610173.

2. de Bont JM, Holt Bv, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. 2004; Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 18:2032–5. DOI: 10.1038/sj.leu.2403538. PMID: 15483674.

3. Stock W, La M, Sanford B, et al. 2008; What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 112:1646–54. DOI: 10.1182/blood-2008-01-130237. PMID: 18502832. PMCID: PMC2518876.

4. Moon EK, Park HJ, Oh CM, et al. 2014; Cancer incidence and survival among adolescents and young adults in Korea. PLoS One. 9:e96088. DOI: 10.1371/journal.pone.0096088. PMID: 24789075. PMCID: PMC4006908.

5. Harrison CJ. 2009; Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 144:147–56. DOI: 10.1111/j.1365-2141.2008.07417.x. PMID: 19006567.

6. Robinson HM, Broadfield ZJ, Cheung KL, et al. 2003; Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia. 17:2249–50. DOI: 10.1038/sj.leu.2403140. PMID: 14523475.

7. Yang M, Yi ES, Kim HJ, Yoo KH, Koo HH, Kim SH. 2017; Intrachromosomal amplification of chromosome 21 in Korean pediatric patients with B-cell precursor acute lymphoblastic leukemia in a single institution. Blood Res. 52:100–5. DOI: 10.5045/br.2017.52.2.100. PMID: 28698845. PMCID: PMC5503886.

8. Roberts KG, Li Y, Payne-Turner D, et al. 2014; Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 371:1005–15. DOI: 10.1056/NEJMoa1403088. PMID: 25207766. PMCID: PMC4191900.

9. Yasuda T, Tsuzuki S, Kawazu M, et al. 2016; Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 48:569–74. DOI: 10.1038/ng.3535. PMID: 27019113.

10. Coustan-Smith E, Mullighan CG, Onciu M, et al. 2009; Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10:147–56. DOI: 10.1016/S1470-2045(08)70314-0. PMID: 19147408. PMCID: PMC2840241.

11. Patrick K, Wade R, Goulden N, et al. 2014; Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 166:421–4. DOI: 10.1111/bjh.12882. PMID: 24708207.

12. Jain N, Lamb AV, O'Brien S, et al. 2016; Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 127:1863–9. DOI: 10.1182/blood-2015-08-661702. PMID: 26747249. PMCID: PMC4915808.

13. Siegel SE, Stock W, Johnson RH, et al. 2018; Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol. 4:725–34. DOI: 10.1001/jamaoncol.2017.5305. PMID: 29450465.

14. Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. 2012; Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 87:472–8. DOI: 10.1002/ajh.23149. PMID: 22388572.

15. Kim YA, Ju HY, Park HJ, et al. 2019; Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients. Br J Haematol. [Epub ahead of print]. DOI: 10.1111/bjh.16242. PMID: 31612474.

16. Hayakawa F, Sakura T, Yujiri T, et al. 2014; Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 4:e252. DOI: 10.1038/bcj.2014.72. PMID: 25325302. PMCID: PMC4220650.

17. Toft N, Birgens H, Abrahamsson J, et al. 2018; Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 32:606–15. DOI: 10.1038/leu.2017.265. PMID: 28819280.

18. Toft N, Birgens H, Abrahamsson J, et al. 2016; Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 96:160–9. DOI: 10.1111/ejh.12562. PMID: 25867866.

19. Stock W, Luger SM, Advani AS, et al. 2019; A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 133:1548–59. DOI: 10.1182/blood-2018-10-881961. PMID: 30658992. PMCID: PMC6450431.

20. Rytting ME, Jabbour EJ, Jorgensen JL, et al. 2016; Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 91:819–23. DOI: 10.1002/ajh.24419. PMID: 27178680. PMCID: PMC5558853.

21. White VM, Skaczkowski G, Pinkerton R, et al. 2018; Clinical management of Australian adolescents and young adults with acute lymphoblastic and myeloid leukemias: a national population-based study. Pediatr Blood Cancer. 65:e27349. DOI: 10.1002/pbc.27349. PMID: 30039912.

22. Gupta S, Pole JD, Baxter NN, et al. 2019; The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: an IMPACT Cohort study. Cancer Med. 8:2095–103. DOI: 10.1002/cam4.2096. PMID: 30912628. PMCID: PMC6536996.

23. Parsons HM, Penn DC, Li Q, et al. 2019; Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States. Pediatr Blood Cancer. 66:e27426. DOI: 10.1002/pbc.27426. PMID: 30256525. PMCID: PMC6249090.

24. Lee S, Chung NG, Cho BS, et al. 2010; Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia. Leukemia. 24:2110–9. DOI: 10.1038/leu.2010.217. PMID: 20882049.

25. Seftel MD, Neuberg D, Zhang MJ, et al. 2016; Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 91:322–9. DOI: 10.1002/ajh.24285. PMID: 26701142. PMCID: PMC4764423.

26. Muffly L, Li Q, Alvarez E, et al. 2019; Hematopoietic cell transplantation in young adult acute lymphoblastic leukemia: a united states population-level analysis. J Adolesc Young Adult Oncol. 8:254–61. DOI: 10.1089/jayao.2018.0140. PMID: 30657424. PMCID: PMC6588119.

27. Hangai M, Urayama KY, Tanaka J, et al. 2019; Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults. Biol Blood Marrow Transplant. 25:1597–602. DOI: 10.1016/j.bbmt.2019.04.014. PMID: 31002992.

28. Slayton WB, Schultz KR, Kairalla JA, et al. 2018; Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's Oncology Group trial AALL0622. J Clin Oncol. 36:2306–14. DOI: 10.1200/JCO.2017.76.7228. PMID: 29812996. PMCID: PMC6067800.

29. Schultz KR, Carroll A, Heerema NA, et al. 2014; Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 28:1467–71. DOI: 10.1038/leu.2014.30. PMID: 24441288. PMCID: PMC4282929.

30. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. 2013; Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 98:e146–8. DOI: 10.3324/haematol.2013.095372. PMID: 24186319. PMCID: PMC3815191.

31. Mayfield JR, Czuchlewski DR, Gale JM, et al. 2017; Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 64:e26328. DOI: 10.1002/pbc.26328. PMID: 27860260. PMCID: PMC5366086.

32. Maude SL, Laetsch TW, Buechner J, et al. 2018; Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 378:439–48. DOI: 10.1056/NEJMoa1709866. PMID: 29385370. PMCID: PMC5996391.

33. Park JH, Rivière I, Gonen M, et al. 2018; Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 378:449–59. DOI: 10.1056/NEJMoa1709919. PMID: 29385376. PMCID: PMC6637939.